Please login to the form below

Not currently logged in
Email:
Password:

Former FDA adviser joins Precision for Medicine

Vicki Seyfert-Margolis appointed chief of science and strategy at life science research company

Precision for Medicine Vicki Seyfert-Margolis Precision for Medicine has appointed former US FDA senior adviser Dr Vicki Seyfert-Margolis to the role of chief of science and strategy.

Dr Seyfert-Margolis served as senior adviser, regulatory science and innovation at the US regulator, reporting directly to the commissioner.

During this time, she led the FDA's regulatory science and personalised medicine initiative, as well as strategies for promoting innovation in drug development.

Prior to her time with the FDA, Dr Seyfert-Margolis was chief science officer at the Immune Tolerance Network, a global research initiative to discover biomarkers for autoimmune disorders.

In her new role at Precision for Medicine, which provides research support to life science companies, Dr Syfert-Margolis will guide the company's scientific strategy and provide insight and support for its clients.

“Precision for Medicine shares my vision for the future of healthcare - one where the patient is not just the end user, but the focal point of all aspects of drug, diagnostic, and device development,” said Dr Seyfert-Margolis.

19th April 2013

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Virtual meeting technologies for reducing emissions and waste in the healthcare industry
...
Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...